SUMMARY Although cardiac effects of growth hormone (GH) and insulin-like growth factor (IGF)-I have been reported in experimental models of heart failure and in human dilated cardiomyopathy, the IGF system has not been comprehensively assessed in the failing heart. We therefore localized the IGF system in the left ventricle during congestive heart failure after myocardial infarction (MI) in the rat. The left anterior descending coronary artery was ligated in adult female Sprague-Dawley rats and hearts were examined after 6 months when congestive heart failure had developed. In situ hybridization histochemistry was used to localize mRNA for the components of the IGF system in the left ventricle of sham and congestive heart failure animals. We were able to detect changes in the spatial distribution of mRNA for IGF-I and IGF binding proteins 3, 4, 5, and 6 in the left ventricle during congestive heart failure after MI. IGF-I and the binding proteins were predominantly increased in the infarct/peri-infarct area of the left ventricle. Other components of the IGF system were indistinguishable from the low to undetectable levels in sham-operated rats. These results demonstrate that the IGF system is altered in the failing heart and suggest that the IGF system plays an important role in the response of the heart to MI and consequent failure. 
Insulin-like growth factor (IGF)-I stimulates tissue growth and differentiation in a paracrine, autocrine, and/or endocrine fashion (Bach and Rechler 1995) . One of the major regulators of IGF-I is growth hormone (GH). Although most actions of IGF-I are mediated through the IGF-I receptor, its activity is also precisely modulated by a family of at least six structurally related IGF binding proteins (IGFBPs 1-6) present in the circulation and in extravascular tissues. The IGFBPs may inhibit or potentiate IGF action and provide a flexible means of regulation of IGF activity .
Congestive heart failure (CHF) is the final common pathway of many cardiovascular diseases, such as coronary artery disease and hypertension. CHF is considered to be an irreversible and progressive process characterized by ventricular dilatation and hypertrophy, a process known as remodeling, and by diminished pump performance.
Changes in expression of components of the cardiac IGF system have been reported in different models of cardiac ischemia, including acute myocardial infarction (MI) (Reiss et al. 1994) , ischemia/reperfusion (Schaper et al. 1994) , and microembolization of the coronary artery (Kluge et al. 1995) . In the rat, acute coronary artery occlusion leads to increases in myocyte IGF-I and IGF-I receptor mRNA levels after 2 days (Reiss et al. 1994) . This is the first study to assess all components of the cardiac IGF system (ligands, receptors, and IGFBPs) at the cellular level in normal or abnormal left ventricle (LV). Furthermore, we describe in detail the endogenous responses of the IGF system in the rat LV 6 months after MI, when CHF is firmly established. This is a clinically relevant time point because CHF is a progressive disease. Furthermore, it is pathophysiologically relevant because remodeling continues even though the scar is mature.
Surgical Production of MI
The rat model of MI resulting in CHF has been extensively used to examine the efficacy of therapeutic interventions in cardiac remodeling and survival (Pfeffer et al. 1987; Burrell et al. 1998 ). In this model, left ventricular free-wall MI was induced in Sprague-Dawley rats by ligation of the proximal left anterior descending (LAD) artery. Sham-operated rats underwent an identical operation but the suture was not tied. All biochemical, structural and histological measurements were carried out 6 months after MI.
Biochemical, Hormonal, and Cardiovascular Structural Data
Six months after operation, rats were sacrificed and trunk blood was collected into EDTA tubes for measurement of atrial natriuretic peptide (ANP) and plasma renin activity 
Figure 1
Macroscopic autoradiographs demonstrating levels of signal produced by in situ hybridization histochemistry in sections of sham operated (top row) and congestive heart failure (CHF) left ventricle (LV) (lower two rows). Both anti-sense (AS) and sense (S) control are shown. Increasing levels of signal are represented by a gray scale, with black being the highest density of signal. The infarcted area of the CHF LV is present where thinning of the LV wall has occurred. Insulin-like growth factor(IGF)-II and IGF binding proteins (BP)s-1 and -2 are not shown because expression was low. (Burrell et al. 1998) . Lungs were removed and weighed. The LV/interventricular septum, right ventricle (RV), right atrium (RA), and left atrium (LA) were dissected from the heart and weighed.
Infarct Size
The LV/interventricular septum was fixed in 10% buffered formalin. Each LV was sectioned at four levels from the base to the apex and paraffin-embedded. Sections were cut and stained with Masson's trichrome, and hematoxylin and eosin. The mean epicardial and endocardial scar circumference was compared to total LV circumference to calculate total infarct size (Pfeffer et al. 1987 ).
In Situ Hybridization Histochemistry
Four-m sections were cut from each level from CHF and sham-operated (n ϭ 4/group) hearts for in situ hybridization histochemistry, as previously described (Price et al. 1995) . Le Roith; National Institutes of Health, Bethesda, MD), as previously described (Price et al. 1995) . RNA probes were synthesized in 20-l reactions containing 100 Ci [ 35 S]-CTP (1000-1500 Ci/mmol; NEN Life Science Products, Boston, MA), 40 mmol/liter Tris-HCl, pH 7.5, 6 mmol/liter MgCl 2 , 2 mmol/liter spermidine, 10 mmol/liter NaCl, 10 mmol/liter DTT, 660 mol/liter each of ATP, GTP, and UTP, 20 U RNasin, 100 ng linearized DNA template, and 20 U of SP6, T3, or T7 RNA polymerase. The reaction was incubated at 37C for 90 min, after which the DNA template was digested with 1 U of DNase I for 15 min at 37C. RNA probes were ethanol-precipitated with yeast RNA as a carrier. Enzymes and reagents were obtained from Promega (Madison, WI). Purified RNA probes were adjusted to an average length of 150 bases by alkaline hydrolysis (Cox et al. 1984) . All transcripts were assessed for integrity and successful hydrolysis by electrophoresis through a 5% acrylamide/urea gel. The average specific activity of the RNA probes generated was 3 ϫ 10 9 cpm/ g RNA.
Labeling of RNA Probes

Hybridization
Before hybridization, sections were dewaxed, hydrated in graded ethanol and ultrapure water (Milli-Q Purification Systems; Millipore Corporation, Bedford, MA), treated with Pronase E (Sigma Chemical; St. Louis, MO) (125 mg/ml), dehydrated in 70% ethanol, and air-dried. The 35 S-labeled RNA probes (5 ϫ 10 5 cpm/25 l hybridization buffer) were added to a hybridization buffer consisting of 300 mmol/liter NaCl, 10 mmol/liter Tris-HCl, pH 7.5, 10 mmol/liter Na 2 HPO 4 , pH 6.8, 5 mmol/liter EDTA, pH 8.0, 1 ϫ Denhardt's solution, 50 mg/ml yeast RNA, 50% deionized formamide, and 10% (w/v) dextran sulfate. The hybridization buffer containing labeled probe was preheated to 85C (5 min). Appropriate volumes were placed on the sections, which were then coverslipped and placed in humidified (50% formamide) chambers for 14-16 hr at 60C. After hybridization, coverslips were removed and slides were washed in 2 ϫ standard saline citrate (2 ϫ SSC: 0.3 mol/liter NaCl, 0.33 mol/liter Na 3 C 6 H 5 O 7 .2H 2 O) containing 50% formamide preheated to 55C, and then washed in 2 ϫ SSC/50% formamide at 55C for 1.5 hr. Sections were then washed in several changes of RNase A buffer (10 mmol/liter Tris-HCl, pH 7.5, 1 mmol/liter EDTA, pH 8.0, 0.5 mol/liter NaCl) preheated to 37C and then treated with 150 g/ml RNase A in RNase A buffer for 1 hr at 37C, followed by a wash in 2 ϫ SSC at 55C for 45 min. After final dehydration through graded ethanol, slides were air-dried and autoradiographed with Kodak XAR (Eastman Kodak; Rochester, NY) film for 1-3 days at room temperature. Slides were then dipped in photographic emulsion (Amersham; Poole, UK), stored with desiccant at 4C for 14-21 days, developed in Kodak D19, fixed in Ilford Hypam, and stained with hematoxylin for cellular localization.
Quantitation of Macroscopic Autoradiographs
Quantitation was carried out using a microcomputer imaging device (MCID) (Imaging Research; St Catherines, Ont, Canada) run by an IBM PC. Four sense and four antisense sections from each animal were used for quantitation. In CHF hearts, the hypertrophied LV and infarct/peri-infarct regions were quantitated separately. The optical density of the autoradiographs was calibrated in terms of radioactivity density by reference to 14 C radioactive standards (Amersham) carried through the procedures. 14 C radioactive standards can be used to calibrate 35 S signal in tissue (Le Moine et al. 1994) . A standard curve was generated, enabling the density of radioactive labeling of LV sections to be determined. Results are expressed as a specific labeling (using anti-sense probes) minus nonspecific labeling (using sense probes) in "nCi/g equivalent."
Immunohistochemistry Immunohistochemistry for macrophages was carried out on protease-digested 4-m paraffin sections of formalin-fixed LV. Standard techniques using a rat macrophage antibody, AIAD51240 (Accurate Chemicals; Westbury, NY) at a dilution of 1:200 and the Elite Vectastain ABC kit (Vector Laboratories; Burlingame, CA) were employed.
Statistics
Results are presented as mean Ϯ SEM. Comparisons of tissue weights and vasoactive hormone levels were made by un- 
a Values representing levels of ISHH signal present over specific structures in the sham and CHF LV. Values were obtained by grading the levels of signal from nonspecific levels (Ϫ) to very dense, tissue difficult to see through mass of silver grains (ϩϩϩ). IGF, insulin-like growth factor; CHF, congestive heart failure. . Signal representing IGFBP-5 mRNA is detectable over the endothelial cells of a capillary in the pericardium. In addition, labeling of particular cells in the myocardium is evident (arrow) (E,F). IGFBP-5 mRNA is also seen over clusters of cells in the myocardium that surround an arteriole (G,H). In H, some fluorescing of the endothelium occurs and should not be confused with specific silver grains. All micrographs at the same magnification.
paired t-tests. Quantitative in situ hybridization variables were log-transformed before statistical analysis to stabilize variance. Comparisons were made using one-way ANOVA followed by a Scheffe F-test. Results were considered significant when pϽ0.05.
Results
Coronary Artery Ligation in the Rat Results in CHF After 6 Months
The average size of MI in CHF rats was 39 Ϯ 2%. No sham-operated animal had evidence of cardiac damage. All rats grew normally over the study period, and body weights in sham and CHF rats were not different (Table 1) . CHF rats were characterized by increased relative LV, RV, LA, RA, and lung masses (Table 1) , consistent with the presence of CHF (Burrell et al. 1996) . Further evidence of CHF was the elevation in plasma ANP levels in CHF rats (Table 1) . As shown previously (Hodsman et al. 1988) , there is no activation of the renin-angiotensin system as indicated by normal PRA (Table 1) in this model of compensated CHF.
IGF-I mRNA Is Increased in the Peri-infarct and Infarct Zones
After MI, there was a significant increase in IGF-I mRNA expression in the peri-infarct/infarct area (pϭ 0.0016; Figure 1 ; Table 2 ). This was particularly evident in the cellular infiltrate (Figures 2A and 2B ), endocardium (Table 3) , and blood vessels within the infarct/peri-infarct zone. However, there was little expression of IGF-I mRNA in the hypertrophied LV away from the infarct. No detectable IGF-I mRNA signal was observed in the LV of sham-operated rats ( Figure 1 ; Table 3 ). In contrast, arterial endothelium was the sole site of expression of IGF-II mRNA in sham LV and was unchanged in the hypertrophying LV or infarct/peri-infarct regions of CHF LV (Table 3) . IGF-I receptor mRNA was moderately expressed in myocardial cells of sham and CHF LV (Table 3) . A similar level of signal representing IGF-I receptor mRNA was also seen in the infarct and peri-infarct cellular infiltrate (Tables 2 and 3) .
Cell-specific Localization of mRNA for IGFBPs in Normal LV
In sham-operated rats with normal LV, IGFBP-3 mRNA signal was observed over individual cells of the endocardium, pericardium, over the conducting system, and over cells on the aortic side of the aortic valve ( Figures 3A and 3B , Table 4 ).
Signal representing IGFBP-4 mRNA was abundant over endothelial cells of blood vessels ( Figures 3C and  3D ) and, to a lesser extent, over individual cells of the valve leaflet (Table 4) .
The conducting system and blood vessels within the pericardium showed high levels of IGFBP-5 mRNA hybridization in sham LV (Figures 3E and 3F ; Table  4 ). In contrast, vessels within the myocardium were not labeled, but groups of cells surrounding the vessels were (Figures 3G and 3H ; Table 4 ); these may represent bundles of conducting fibers, infiltrating cells, or nerves. Individual cells throughout the myocardium and within the endocardium were also labeled (Figures 3E and 3F ; Table 4 ). 
a Values representing levels of ISHH signal present over specific structures in the sham and congestive heart failure (CHF) left ventricle. Values were obtained by grading the levels of signal from nonspecific levels (Ϫ) to very dense, tissue difficult to see through mass of silver grains (ϩϩϩ). IGF, insulin-like growth factor; IG-FBP, insulin-like growth factor binding protein. In sham LV, low-abundance signal representing IG-FBP-6 mRNA was observed at the junction of valve leaflets and the myocardium in an area that may represent part of the A-V node, as well as over cells surrounding arteries (Table 4) . Signal representing IG-FBP-1 and IGFBP-2 was very low over the myocardium in sham LV (Table 4) .
Expression of IGFBPs Is Elevated over the Scar and Peri-infarct Zone of Infarcted LV
Expression of IGFBPs 1 and 3-6 was significantly elevated in the infarct and peri-infarct regions (Figure 1 ; Table 2 ) of CHF LV pϭ0.01; pϭ0.0154; pϽ0.0001; pϭ0.02; pϭ0.0016) . IGFBP-4 mRNA was also increased in the hypertrophied LV of CHF rats (pϭ 0.0002).
At the microscopic level, IGFBP-3 (Figures 4A and 4B) and IGFBP-4 ( Figures 4C and 4D ) mRNA signals were detectable over the infiltrating cells and throughout the cells of the connective tissue of the peri-infarct area (Table 4) . Cells of the myocardium away from the infarct in the hypertrophying LV were also labeled for IGFBP-4 mRNA. IGFBP-5 mRNA labeling of infarct and peri-infarct infiltrating cells was not as intense as those of IGFBP-3 and IGFBP-4 but was largely confined to cells lining the blood vessels in these regions (Figures 4E and 4F ; Table 4 ). This was in contrast to the lack of IGFBP-5 mRNA labeling over blood vessels throughout the hypertrophied LV.
IGFBP-6 mRNA was moderately expressed over the entire infarct and peri-infarct area, including infiltrating cells and cells of the mature scar, but was not increased over vessels (Figures 4G and 4H ; Table 4 ). Signal representing IGFBP-1 or IGFBP-2 mRNA was very low over the entire myocardium in both sham and CHF left ventricles, including the scar (Table 4) . Although the increase in IGFBP-1 mRNA in the infarct/peri-infarct area was statistically significant, levels of signal were very low and, given the lack of increase in signal over specific cells at the microscopic level, the biological significance of this result is questionable. Furthermore, the rise in IGFBP-1 mRNA was inconsistent because it was seen in only two of the four animals.
Pericardial Expression of IGF-I and IGFBP 3-6 mRNA Is Elevated in Infarcted LV Infiltrating cells of the pericardium of CHF LV were abundantly labeled for IGFBP-3 ( Figures 5A and 5B ), IGFBP-4 ( Figures 5C and 5D ), IGFBP-5 ( Figures 5E  and 5F ), IGFBP-6 ( Figures 5G and 5H) , and IGF-I ( Figures 5I and 5J ) mRNAs (Tables 3 and 4) .
Macrophages Were Not the Sole Type of Infiltrating Cell to Express Components of the IGF System
Immunohistochemistry for macrophages was carried out on serial sections of LV. The sections used for immunohistochemistry were adjacent to those used for in situ hybridization. This enabled us to determine whether labeling of cells in the infarct/peri-infarct area and pericardium with in situ hybridization was confined to macrophages. We found that signal for IGF-I and IGFBP-3, -4, -5, and -6 mRNA co-localized with macrophage staining; however this was not the only cell type to express the mRNA (not shown).
Discussion
This is the first study to localize the components of the IGF system at the cellular level in the LV of normal and infarction-induced failing rat hearts. Coronary ligation in the rat produces a uniform model of CHF characterized by increased cardiac and lung weight and increased plasma atrial natriuretic peptide levels.
In this model, mRNA for IGF-I and IGFBP-3-6 was significantly increased in the infarct/peri-infarct area of the failing LV. However, there was little change in the hypertrophying myocardium, with only IGFBP-4 showing a significant increase. The components of the IGF system each had unique patterns of cellular distribution, with different cells of the LV, including infiltrating cells, vessels, valve leaflet cells, and myocytes, being labeled.
The heart is a GH-dependent organ (Sacca et al. 1994) , and administration of GH and IGF-I has beneficial effects on the heart in the coronary artery-ligated rat (Duerr et al. 1995; Yang et al. 1995) . In addition, overexpression of human IGF-I in myocytes improves recovery after MI in transgenic mice (Li et al. 1997) . However, in patients with dilated cardiomyopathy, administration of GH for 3 months produced differing results, with one study demonstrating clinical improvement whereas another did not (Fazio et al. 1996; Osterziel et al. 1998) . Administration of GH/IGF-I in the setting of CHF may alter heart function by affecting local levels of the IGF system. To further clarify the mechanism whereby GH and IGF-I treatment may be effective, studies such as the present one evaluating responses of the endogenous IGF system to cardiac damage are necessary.
Our study demonstrates that IGF-I mRNA remained significantly elevated in the peri-infarct and infarct areas but not in the hypertrophied LV 6 months after MI. Previous studies using a rat model of MI have shown that IGF-I immunoreactivity is increased in the viable myocardium immediately adjacent to the infarct and, to a lesser extent, over myocardial tissue distant from the infarct (24 hr and 20 days after infarct) (Krishnamurthi et al. 1997 ). IGF-I may stimulate cell hypertrophy and proliferation of myocytes as well as fibroblasts and endothelial cells which are involved in repair of the damaged area and angiogenesis (Kluge et al. 1995) . The IGF system is known to be involved in wound healing of other tissues, including skin (Brown et al. 1997 ) and, interestingly, in the inhibition of apoptosis (Parrizas et al. 1997 ), a process involved in remodeling.
The role of the IGFBPs in the setting of CHF is complex because they may stimulate or inhibit IGF actions . In the first 3 days after myocardial microembolization in porcine heart, there are elevations in IGFBP-3 and -6 mRNA and a decline in IGFBP-5 mRNA in the ischemic tissue (Kluge et al. 1997) . In contrast, there were no changes in control tissue from the same heart. In this study, 6 months after MI, IGFBP-3, -5, and -6 mRNAs were elevated in the infarct and peri-infarct zone in CHF rats, and IG-FBP-4 was increased in the infarct/peri-infarct zone and in the hypertrophying LV. Because IGF-I/IGFBP-3 complexes promote wound healing , elevated levels of IGFBP-3 and IGF-I mRNAs in the infarct and peri-infarct regions in CHF rats may be involved in scar formation. IGFBP-4 is inhibitory in vitro , and therefore, the intense localization of IGFBP-4 mRNA to areas of chronic tissue damage and repair may represent an attempt to limit IGF action at these sites to prevent hyperproliferation and fibrosis (Delafontaine 1995) . IGFBP-5 mRNA was localized to the endothelial cells of vessels in the infarct/peri-infarct region but not in the hypertrophying LV or sham LV, where it may translocate systemic IGF-I into the heart. Although their precise roles cannot be defined from this study, increased expression of IGFBPs in specific locations in the CHF heart is likely to finely regulate IGF-I effects on remodeling and tissue repair. Changes in the expression of the IGF system in this model may be the result of either ischemia-induced CHF or a response to injury. However, regulation of mRNA away from the ischemic area, such as an increase in IGFBP-4 mRNA in the hypertrophying LV, suggests that this is not merely a response to injury.
Although the infiltrating inflammatory cells of the infarct and peri-infarct region were the major cell types to show an increase in IGFBP mRNA, they were not the only cell types to do so. For example, IGFBP-3 and -4 mRNA were increased in connective tissue cells, such as fibroblasts, and IGFBP-5 mRNA was increased over vascular endothelial cells in the infarcted region. This lends support to the contention that the response is not purely confined to infiltrating inflammatory cells but also involves the resident cells of the myocardium. Furthermore, resident fibroblasts and macrophages distant from the infarct did not have high levels of expression, indicating that the increased expression in the peri-infarct/infarct region was not solely due to the infiltration of cells with high levels of basal expression.
This study has demonstrated significant changes in the expression of components of the IGF system in failing myocardium 6 months after infarction. There was a dramatic upregulation of the IGF system in the infarct/peri-infarct area, an area of repair and remodeling, suggesting that the IGF system plays an important role in the response of the heart to ischemic injury and consequent cardiac failure. Because the results of the present study at 6 months after myocardial infarction differ from those of previous studies examining the IGF system soon after myocardial infarction (Kluge et al. 1997; Krishnamurthi et al. 1997) , temporal studies are needed to determine the time course of such changes in the cardiac IGF system.
